Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

NCT00051012 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

86

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, T-Cell, Cutaneous
Mycosis Fungoides
Sezary Syndrome

Interventions

DRUG: ONTAK

Sponsor

Eisai Inc.